Advances in the Treatment of Melanoma — Sloan-Kettering At the plenary session of the June 2011 annual meeting of the American Society of Clinical Oncology (ASCO), our doctors presented positive results from two separate studies of new therapies for the treatment of advanced melanoma. In this video, medical oncologists Paul Chapman and Jedd Wolchok discuss their findings and illustrate Memorial Sloan-Kettering's commitment to translational research, bringing scientific advances from the laboratory to patients. One study showed that a new drug decreased the risk of death by 63 percent for people with advanced melanoma. Vemurafenib, an oral medication, targets and silences a particular gene mutation. The other study revealed that the FDA-approved ipilimumab (Yervoy™) bolsters the body's immune system in fighting advanced melanoma. This therapy could extend life when combined with traditional chemotherapy. These two important advances in the treatment of melanoma could lead to a combination approach in the future.